Early outcomes of migraine after erenumab discontinuation: data from a real-life setting-Reference-Cited by-同舟云学术

Early outcomes of migraine after erenumab discontinuation: data from a real-life setting

Published:2021-01-02 Issue:8 Volume:42 Page:3297-3303
ISSN:1590-1874
Container-title:Neurological Sciences
language:en
Short-container-title:Neurol Sci

Author:

De Matteis Eleonora,Affaitati Giannapia,Frattale Ilaria,Caponnetto Valeria,Pistoia Francesca,Giamberardino Maria Adele,Sacco Simona^ORCID,Ornello Raffaele

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Neurology (clinical),Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10072-020-05022-z.pdf

Reference16 articles.

1. (2019) Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(5):459–480. https://doi.org/10.1016/s1474-4422(18)30499-x

2. Stovner LJ, Andree C (2010) Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain 11(4):289–299. https://doi.org/10.1007/s10194-010-0217-0

3. Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB (2010) Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia 30(9):1065–1072. https://doi.org/10.1177/0333102409355601

4. Martelletti P (2015) The therapeutic armamentarium in migraine is quite elderly. Expert Opin Drug Metab Toxicol 11(2):175–177. https://doi.org/10.1517/17425255.2015.982089

5. Martelletti P, Edvinsson L, Ashina M (2019) Shaping the future of migraine targeting calcitonin-gene-related-peptide with the disease-modifying migraine drugs (DMMDs). J Headache Pain 20(1):60. https://doi.org/10.1186/s10194-019-1009-9

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine;Cephalalgia;2024-09

2. Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results;Journal of Neurology;2024-06-13

3. Long–Term Outcome After Discontinuation of CGRP-Targeting Therapy for Migraine;Current Pain and Headache Reports;2024-04-29

4. Clinical Evaluation After Discontinuation of Galcanezumab in Japanese Patients with Episodic and Chronic Migraine: Analysis of a Randomized, Placebo-Controlled Trial and Open-label Extension Study;Neurology and Therapy;2024-04-06

5. Developments in targeting calcitonin gene-related peptide;Expert Review of Neurotherapeutics;2024-04